Zydus Cadila has received an approval from the USFDA to market Exemestane tablets (US RLD, AROMASW tablets), 25 mg, the company said in a statement to the exchanges on Friday.
The company will produce these tablets in its formulations manufacturing facility at SEZ, Ahmedabad. “The estimated sales of Exemestane tablets are $68.6mn,” said Cadila in a press note.
“These tablets are belongs to the group of medicines called aromatase inhibitor used in women after menopause for the treatment of early breast cancer (cancer that has not spread outside the breast) in women who have cancer that needs the female hormone estrogen to grow have had other treatments for breast cancer for 2-3 years and are switching to Exemestane to complete five years in a row of hormonal therapy,” the company said. These tablets are also used in the treatment of advanced breast cancer after treatment with other therapies.
The group now has 220 approvals and has so far filed over 330 ANDAs, since the commencement of the filing process in FY04, the company added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.